This is a Phase II study for the use of T-cell replete reduced intensity conditioning (RIC) haploidentical donor allogeneic hematopoietic cell transplantation (HaploHCT) for individuals with high-risk non-malignant diseases who lack a suitable HLA-matched sibling donor.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
5
Reduced intensity conditioning (RIC) with rabbit ATG, fludarabine, cyclophosphamide, thiotepa and low dose (2 Gy) total body irradiation followed by T-cell replete, unmanipulated, haploidentical related donor stem cell transplant (HaploHCT) and post-transplant cyclophosphamide (PTCy)
Masonic Caner Center at University of Minnesota
Minneapolis, Minnesota, United States
Neutrophil Recovery
Incidence of neutrophil recovery by day +42
Time frame: Day 42
Overall Survival (OS)
Incidence of overall survival at 1 year
Time frame: 1 year
Primary Graft Failure (neutropenic and non-neutropenic)
Incidence of primary graft failure (neutropenic and non-neutropenic) by day +42
Time frame: Day 42
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.